alexa Adjuvant Properties Of Outer-membrane-vesicle In Hepatitis B Surface Based Vaccine
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Arfa Moshiri
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Objective: The outer membrane vesicle of Neisseria meningitidis serogroup B (OMV) is among the more studied components with microbial origin, which could be applied as an adjuvant. In the present study, OMV of N. meningitidis serogroup B was applied as an adjuvant co-administrated with the HBs Ag to evaluate the efficiency of this immunization strategy for the promotion of efficient humoral/cellular responses against Hepatitis B virus. Methods: OMVs were prepared as previously described. In brief, N. meningitidis serogroup B strain (CSBPI, G-245) was grown under controlled submerge cultural condition in a fermentor containing modified Frantz medium. The outer membrane vesicles (OMVs) were extracted in Tris-HCl buffer, containing EDTA and deoxycholate. Purification of the OMVs was done by sequential centrifugation at 20, 000 followed by ultracentrifugation at 125, 000. Purified recombinant hepatitis B surface antigen (HBsAg) was prepared from the production and research complex of Pasteur Institute of Iran (Karaj, Iran). Four animal groups were immunized by intranasal inoculation with HBs, HBs+OMV mixture, HBs+complete/incomplete Freund?s adjuvant (C/IFA) and OMV. Two booster immunizations were carried out three and six weeks after the first immunization. Indirect enzyme-linked immunosorbent assay (ELISA) was applied to assess total and subtype antibody responses against HBsAg. Results & Conclusion: Analysis of anti-HBsAg responses elicited in immunized BALB/c mice following different immunization regimens indicated OMV+HBsAg as an immunopotent combination which significantly induced anti-HBsAg IgG with IgG2a dominancy. In accordance to previous study, evaluation of humoral responses following the immunization with HBsAg, HBsAg+C/IFA and HBsAg+OMV indicated the potency of HBsAg vaccine in all the administrated formulations to efficiently induce humoral responses against HBsAg. Although the highest level of antibodies was raised in HBsAg +C/IFA injected animals, however, the promoted response in HBsAg +OMV immunized group was comparable with HBsAg +C/IFA, indicating the capability of HBsAg +OMV immunogen for humoral response induction. All of these responses are TH1 oriented with IgG2a sub-type predominance. The highest IgG2a titer has been detected in the sera of mice immunized with HBsAg +C/IFA respectively followed by HBsAg +OMV and HBsAg. Although the most augmented anti-HBs humoral responses were detected in the sera of HBsAg +C/IFA-immunized mice, however, titer of total anti-HBs antibody and raised IgG2a was significantly increased by the application of OMV adjuvant and was comparable with the HBsAg +C/IFA regimen. Considering that OMV is a human-compatible adjuvant, this finding argues in support of probable application of OMV in HBsAg -based vaccine. According to our study, HBsAg combined with OMV seem to be a promising adjuvant in vaccine development against hepatitis B virus.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version